Enhancing the radiosensitivity of cancer cells is one of the most important tasks in clinical radiobiology. Endocrine therapy and radiotherapy are two cancer treatment modalities which are often given together in patients with locallyadvanced breast cancer and positive hormone-receptor status. Oncostatic actions of melatonin are relevant on estrogen-dependent mammary tumors. In the present study, we wanted to evaluate the effects of the combination of ionizing radiation and melatonin on proteins involved in estrogen biosynthesis in breast cancer cells. We demonstrated a role of melatonin in mediating the sensitization of human breast cancer cells to the ionizing radiation by decreasing around a 50% the activity and expression of proteins involved in the synthesis of estrogens in these cells. Thus, melatonin pretreatment before radiation reduces the amount of active estrogens at cancer cell level. Melatonin 1 nM induced 2-fold change in p53 expression as compared to radiation alone.
Introduction
Melatonin is the main secretory product of the pineal gland that participates in the regulation of important physiological and pathological processes, such as the regulation of neoplastic cell growth. Oncostatic actions of melatonin are relevant on tumors corresponding to the mammary gland and especially on estrogen-dependent mammary tumors [1] [2] [3] [4] [5] [6] . Evidence from in vivo studies on animal models and in vitro studies on breast cancer cell lines supports the hypothesis that melatonin's oncostatic effects on hormonedependent mammary tumors are mainly dependent on its ability to interact with the estrogen-signalling pathway [5, 7] . At the mammary tumor cell level, melatonin interferes with the estrogen receptor, modulates estrogen binding, DNA-binding, and transcriptional activity, and counteracts the effects of estrogens, thus behaving as a selective estrogen receptor modulator.
Melatonin, at physiological concentrations, is also able to modulate the synthesis and transformation of androgens and biologically active estrogens in human breast cancer cells, through the inhibition of aromatase, sulfatase and 17β-hydroxysteroid dehydrogenase type 1 activity and expression, and the stimulation of sulfotransferase activity and expression, enzymes involved in the estradiol formation in breast cancer cells, thus behaving as a selective estrogen enzyme modulator [8] [9] [10] .
The identification of estrogen's central role in mammary carcinogenesis has led to investigation of estrogen pathways as major targets for breast cancer therapy. Breast-conserving surgery, radiotherapy for the affected breast, and adjuvant hormone therapy using antiestrogens, like tamoxifen, or aromatase inhibitors, like letrozol, are standard treatments for postmenopausal early breast cancer patients with hormone receptor-positive tumors [11, 12] . Radiotherapy is considered a standard treatment option after surgery and adjuvant endocrine therapy is also universally used [11] . Timely initiation of radiation therapy is critical and contributes to a good recovery. Tamoxifen and letrozole are the current first-line endocrine therapy drugs. Tamoxifen, a selective estrogen receptor modulator, has provided a significant improvement in both local control and global survival rates [11, 13] . Nowadays, it is estimated that tamoxifen may reduce the annual breast cancer death rate by 31% in estrogen receptorpositive mammary tumors [13, 14] . In vivo studies have shown a synergistic effect of concurrent antiestrogen treatment and radiotherapy on tumor cells [12] [13] [14] . Aromatase inhibitors of third generation, which were introduced in the late 1990s, have proven to be superior to tamoxifen for postmenopausal patient [15] . Although limited data on the use of aromatase inhibitors with radiotherapy are available, Azria et al. [16] described that letrozole, a non-steroid selective aromatase inhibitor, sensitizes breast cancer cells to ionizing radiation and Ishitobi et al. [17] described that the administration of aromatase inhibitors after and concurrently with radiotherapy in patients with breast cancer are both reasonable treatment options.
Since melatonin has both antiestrogen and antiaromatase properties [4, 5, 8] , we thought about the possibility that melatonin may regulate the sensitivity of human breast cancer cells to radiotherapy. Recently, our group demonstrated that melatonin pretreatment before radiation sensitizes breast cancer cells to the ionizing effects of radiation by decreasing cell proliferation, inducing cell cycle arrest and downregulating proteins involved in double-strand DNA break repair [18] . In the present study we investigated its effects on radiated human breast cancer cells by regulating proteins involved in estrogen biosynthesis.
Materials and methods

Cells and culture conditions
MCF-7 human breast cancer cells were purchased from the American Tissue Culture Collection (Rockville, MD, USA). They were maintained as monolayer cultures in 75 cm 2 plastic culture flasks in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich, Madrid, Spain) supplemented with 10% fetal bovine serum (FBS) (Biowest, Nuaille, France), penicillin (20 units/ml) and streptomycin (20 μg/ml) (Sigma-Aldrich, Madrid, Spain) at 37ºC in a humid atmosphere containing 5% CO2. the supernatants were added to vials with scintillation cocktail and counted in a beta counter (Beckman LS 6000 IC, Fulleton, CA, USA). The amount of radioactivity measured in [ 3 H]-water was corrected by substracting the blank values from each sample, obtained by incubating dishes containing medium with the tritiated androgen but no cells. The values were also corrected by taking into account the fractional retention of tritium in medium water throughout the processing, utilizing parallel dishes containing medium plus known amounts of [ 3 H]-water (NEN Life Science Products, Boston, MA, USA) through incubation and assay. The fractional retention of tritium in medium water throughout the incubation and processing of samples was always higher than 85%.
Measurement of steroid sulfatase (STS) activity
STS activity in MCF-7 cells was assayed by the formation of estrone from a labelled substrate ( [6, H(N)]-estrone sulfate ammonium salt) [23] . Control and melatonin (1 nM, 10 µM or 1 nM) pretreated (a week) MCF-7 cells were seeded into six-well plates at a density of (1.5 x 10 5 cells / well) in DMEM supplemented with 10% FBS, 20 units/ml penicillin and 20 µg/ml streptomycin and incubated at 37ºC for 24 h in a humid atmosphere containing 5% CO2, to allow for cell attachment before irradiation. Then, cells were irradiated and after 24 hours, media were aspirated and replaced with fresh ones (1 ml per plate) containing 5 pM [6, 
Measurement of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) activity
Activity of 17β-HSD1 was assayed in MCF-7 cells by the formation of E2 from a labelled substrate [2, 4, 6, H(N)]-estrone [24] . Control and melatonin (1 nM, 10 µM or 1 nM) pretreated (a week) MCF-7 cells were seeded into sixwell plates at a density of (1.5 x 10 5 cells / well) in DMEM supplemented with 10% FBS, 20 units/ml penicillin and 20 µg/ml streptomycin and incubated at 37ºC for 24 h in a humid atmosphere containing 5% CO2, to allow for cell attachment before irradiation. Then, cells were irradiated and after 24 hours, media were aspirated and changed for fresh ones (1 ml per plate) containing 2 nM [2, 4, 6, H(N)]-estrone (NEN Life Science Products, Boston, MA, USA) (100 Ci / mM). After 30 min of incubation, the media were transferred to tubes containing 4 ml of diethyl ether, vortexed and centrifuged at 800xg for 5 min.
The aqueous phase was frozen and the resulting organic phase was decanted, evaporated in tubes containing 50 µg of estradiol. 
Statistical analysis
The data are expressed as the mean ± standard errors of the mean (SEM) of six independent experiments. Statistical differences between groups were analyzed by using one way analysis of variance (ANOVA), followed by the Student-Newman-Keuls test. Results were considered as statistically significant at p<0.05.
Results
Effects of ionizing radiation and melatonin on cell proliferation and cytotoxicity
With radiation alone, the MCF-7 cell proliferation decreased in a dosedependent manner and for 8 Gy radiation, the inhibition of cell proliferation was 40% with respect to control non-radiated cells (Fig. 1A) . Treatment with physiologic concentrations of melatonin (1 nM) for 7 days before radiation led to a significantly (p<0.001) higher decrease in cell proliferation in comparison with control radiated cells. Pretreatment with pharmacologic concentrations of melatonin (1 mM and 10 µM) also induced a marked decrease in cell proliferation but was less effective than pretreatment with physiologic concentrations (1 nM) (Fig. 1A) . Figure 1B shows the effect of ionizing radiation and melatonin pretreatment on cytotoxicity. The survival fraction after 8 Gy irradiation dose was reduced 84% with respect to non-radiated cells. Pretreatment with melatonin (1 mM, 10 µM and 1 nM) led to a significantly biggest decline in survival rates, with melatonin concentrations (1 mM) being the most effective in decrease the survival fraction (50 % of reduction when compared to control radiated cells).
Effects of ionizing radiation and melatonin on aromatase activity and expression and aromatase promoter regions pI.3, pII and pI.7 expression
With 8 Gy radiation alone, aromatase activity was significantly (p<0.001) decreased by 40%. Treatment with physiologic concentrations of melatonin (1 nM) for 7 days before radiation led to a significantly higher decrease in aromatase activity ( Fig. 2A) (70% of reduction when compared to control nonradiated cells). Pharmacologic concentrations of melatonin (1 mM) were also effective to reduce (p<0.001) the aromatase activity of breast cancer cells ( Fig. 2A) . With the aim of determining whether the inhibitory effect of melatonin on aromatase activity is due to the downregulation of aromatase expression, we irradiated control and melatonin pretreated MCF-7 cells and after 6 h total RNA was isolated to perform real-time quantitative PCR with specific primers for human aromatase. Radiation (8 Gy) alone significantly decreased (p<0.001) in a half aromatase RNA expression in MCF-7 cells (Fig. 2B ). Physiologic concentrations of melatonin pretreatment before radiation resulted in a significantly higher decreased in aromatase mRNA expression (50% of control radiated cells). Very high pharmacologic concentrations of melatonin (1 mM) were also effective to reduce (p<0.001) the aromatase mRNA expression of breast cancer cells (Fig. 2B) .
To determine the promoters involved in the melatonin control of aromatase expression, we used competitive RT-PCR to amplify each of the promoterspecific transcripts from RNA extracted from MCF-7 cells. As shown in Figure 3 , melatonin 1 nM exerted a significant (p<0.001) inhibition in aromatase expression that is specific to the aromatase promoters I.3, pII and pI.7. Higher concentrations of melatonin were also effective to reduce (p<0.001) the aromatase expression specific to the aromatase promoters I.3, pII and pI.7
( Fig. 3 ).
Effects of ionizing radiation and melatonin on STS activity and expression
In a second set of experiments, the effects of melatonin treatment before radiation on the STS activity and mRNA expression were studied. With radiation alone a significant (p<0.001) decrease in STS activity (30% less activity), the enzyme responsible for the conversion of estrogens to the less potent sulfate conjugated forms, was observed (Fig. 4A) . When MCF-7 cells were pretreated with physiologic concentrations of melatonin (1 nM) the inhibition of STS activity was 50% with respect to control radiated cells. Pretreatment with higher concentrations of melatonin was also effective to reduce (p<0.001) the STS activity (Fig. 4A ).
Radiation alone significantly decreased the expression of STS by 25%.
Treatment with melatonin for 7 days before radiation led to a significantly greater decrease in STS mRNA expression compared with radiation alone and doubled the inhibition (Fig. 4B) .
Effects of ionizing radiation and melatonin on 17β-HSD1 activity and expression
Next, the effects of melatonin treatment before radiation on the 17β-HSD1 activity and mRNA expression were studied. With radiation alone a significant (p<0.001) decrease in 17β-HSD1 activity, the enzyme responsible for the conversion of the relatively inactive estrone to the most potent 17β-estradiol, was observed (Fig. 5A) . When MCF-7 cells were pretreated with physiologic concentrations of melatonin (1 nM) the inhibition of 17β-HSD1 activity was twice as much as that of control radiated cells. Pretreatment with higher concentrations of melatonin (1 mM) was even more effective to reduce (p<0.001) the 17β-HSD1 activity (Fig. 5A ).
Radiation alone significantly also decreased by 20% the expression of 17β-HSD1. Treatment with melatonin for 7 days before radiation led to a significantly greater decrease in 17β-HSD1 mRNA expression compared with radiation alone (Fig. 5B) , with physiologic melatonin concentrations (1 nM)
being the most effective in decrease the 17β-HSD1 mRNA expression (a half of expression than radiated cells).
Effects of ionizing radiation and melatonin on p53 mRNA expression
With 8 Gy radiation alone, the expression of mRNA p53 increased twotimes (p<0.001). Pretreatment with physiologic concentrations of melatonin (1 nM) for 7 days before radiation led to a significantly higher increase in p53 mRNA expression, three-times as big as control non-radiated cells (Fig. 6 ).
Higher concentrations of melatonin (10 µM) were also effective to increase (p<0.001) p53 mRNA expression of breast cancer cells (Fig. 6 ).
Discussion
Endocrine endothelial cells but also present in malignant epithelial cells [36] . Besides this melatonin down-regulatory effect on aromatase activity and expression and on the two main promoters driving aromatase expression in breast cancer, in our study, melatonin also modulates the activity and expression of the STS and 17β-HSD1. The estrone sulfatase pathway is the major route of estrogen formation in breast tumors and the estrogen sulfatase activity is 40-500 times higher than aromatase activity in breast cancer tissues [37, 38] . Radiation alone decreased STS and 17β-HSD1 activity and expression and melatonin pretreatment for one week before radiation enhanced the decrease in STS and 17β-HSD1 activity and expression induced by ionizing radiation. Thus, melatonin pretreatment by down-regulating aromatase, STS and 17β-HSD1 might reduce active estrogens levels at tumoral cell level.
The tumour suppressor p53 is a central factor for the maintenance of genome stability and, consequently, for the suppression of cancer [39] . p53 is upregulated and activated by genotoxic stress, like ionizing radiation, and induces a transcriptional program with effectors promoting apoptosis, cell cycle arrest, senescence and DNA repair [40, 41] . There is growing evidence for a direct role of p53 in the fidelity control of DNA repair to ensure error-free DNA double-strand breaks repair and, therefore, to suppress detrimental genome rearrangements that drive cancer [39, 42] . p53 modulates DNA repair and may assist in the down-regulation of inappropriate recombination in particular through direct interaction and inhibition of repair proteins such as RAD51 [43] .
In addition it has been recently demonstrated that p53 is a negative regulator of aromatase in the breast [44] . Radiation alone increased p53 expression.
Pretreatment of breast cancer cells with physiologic concentrations of melatonin before radiation led to a greater increase of p53 expression. The up-regulation of the expression of p53 and p21WAF1 proteins induced by melatonin has been suggested as an important mechanism through which this indolamine produces antiproliferative effects in human breast cancer cells [45] . Since melatonin pretreatment before radiation sensitizes breast cancer cells to the ionizing effects of radiation by decreasing cell proliferation, inducing cell cycle arrest, downregulating proteins involved in double-strand DNA break repair and estrogen biosynthesis, and p53 promotes cell cycle arrest, DNA repair and aromatase down-regulation, the regulatory action of melatonin on p53 could be a link between melatonin and its modulatory action on sensitivity of breast cancer cells to the ionizing radiation.
In summary, the findings present herein suggest that melatonin enhancement of the radiosensitivity of human breast cancer cells is associated with the modulation of proteins involved in estrogen biosynthesis.
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